HLA class I histocompatibility antigen A alpha chain in complex with KRAS G12V peptide (HLA-A*11:01/KRAS G12V complex)

The HLA-A*11:01/KRAS G12V peptide complex is a molecular structure where the KRAS G12V mutant peptide is presented on the cell surface by the HLA-A*11:01 class I MHC molecule. This presentation is recognized by engineered T cell receptors, enabling targeted immunotherapy approaches for tumors harboring the KRAS G12V mutation—most commonly in lung, colorectal, and pancreatic cancers. The complex is highly stable and shows strong binding affinity, making it a prominent target for neoantigen-directed cellular therapies. Its specificity (both allele- and mutation-dependent) supports patient stratification and the development of precision medicine, but also necessitates careful safety profiling to avoid off-target toxicity. HLA-A*11:01 has a high prevalence in East Asian populations, increasing the therapeutic relevance of this target in these regions.

Other names

HLA-A*11:01-KRAS G12V peptide complexHLA-A11:01-KRAS G12V pMHC complexHLA-A*11:01-KRAS mutant peptide complexKRAS G12V/HLA-A*11:01 neoepitope

TCR-mediated cytotoxicity (engineered TCRs recognize and bind the KRAS G12V peptide presented by HLA-A*11:01, leading to T cell activation and tumor cell killing.)